|
1）Arnold D, Andre T, Bennouna J, et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV + CT: Results of a randomised phase III intergroup study - TML (ML18147). J Clin Oncol. 2012; 30 (suppl; abstr CRA3503)
|
|
|
|
|
2）Allegra CJ, Lakomy R, Tabernero J, et al. Effects of prior Bevacizumab use on outcomes from the VELOUR study: A phase III study of Aflibercept and FOLFIRI in patients with metastatic colorectal cancer after failure of an Oxaliplatin regimen. J Clin Oncol. 2012; 30 (suppl; abstr 3505)
|
|
|
|
|
|
3）Cutsem E, Sobrero A, Siena S, et al. Phase III CORRECT trial of Regorafenib in metastatic colorectal cancer (mCRC). J Clin Oncol. 2012; 30 (suppl; abstr 3502)
|
|
|
|
|
|
4）Kuboki Y, Yoshino T, Yamazaki K, et al. A Multicenter, randomized, double-blind, phase II study of TAS-102 (A) plus best supportive care (BSC) versus placebo (P) plus BSC in patients (pts) with chemotherapy-refractory metastatic colorectal cancer (mCRC). ESMO. 2012 Abstract #6005
|
|
|
|
|
|
5）Tournigand C, Samson B, Scheithauer W, et al. Bevacizumab with or without Erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bevacizumab, in patients with metastatic colorectal cancer: Efficacy and safety results of the International GERCOR DREAM phase III trial. J Clin Oncol. 2012; 30 (suppl; abstr 3500)
|
|
|
|
|
|
6）Bellosillo B, Montagut C, Dalmases A. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine. 2012; 18; 221-3
|
|
|
|